Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine

Journal of Immunology

Volumn 175, Issue 11, 2005, Pages 7226-7234

  Hsu, Cary ^a   Hughes, Marybeth S ^a   Zheng, Zhili ^a   Bray, Regina B ^a   Rosenberg, Steven A ^a   Morgan, Richard A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR; INTERLEUKIN 15 RECEPTOR ALPHA; INTERLEUKIN 2; RETROVIRUS VECTOR; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CODON; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE CONTROL; GENETIC ENGINEERING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSGENE;

EID: 28244460980     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.11.7226     Document Type: Article

References (51)

1. Burton, J. D., R. N. Bamford, C. Peters, A. J. Grant, G. Kurys, C. K. Goldman, J. Brennan, E. Roessler, and T. A. Waldmann. 1994. A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc. Natl. Acad. Sci. USA 91: 4935-4939.
2. Grabstein, K. H., J. Eisenman, K. Shanebeck, C. Rauch, S. Srinivasan, V. Fung, C. Beers, J. Richardson, M. A. Schoenborn, M. Ahdieh, et al. 1994. Cloning of a T cell growth factor that interacts with the β chain of the interleukin-2 receptor. Science 264: 965-968.
3. Dudley, M. E., and S. A. Rosenberg. 2003. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat. Rev. Cancer 3: 666-675.
4. Waldmann, T. A. 2003. IL-15 in the life and death of lymphocytes: immunotherapeutic implications. Trends Mol. Med. 9: 517-521.
5. Malek, T. R., and A. L. Bayer. 2004. Tolerance, not immunity, crucially depends on IL-2. Nat. Rev. Immunol. 4: 665-674.
6. Marks-Konczalik, J., S. Dubois, J. M. Losi, H. Sabzevari, N. Yamada, L. Feigenbaum, T. A. Waldmann, and Y. Tagaya. 2000. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc. Natl. Acad. Sci. USA 97: 11445-11450.
7. Schluns, K. S., K. Williams, A. Ma, X. X. Zheng, and L. Lefrancois. 2002. Cutting edge: requirement for IL-15 in the generation of primary and memory antigen-specific CD8 T cells. J. Immunol. 168: 4827-4831.
8. Oh, S., J. A. Berzofsky, D. S. Burke, T. A. Waldmann, and L. P. Perera. 2003. Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. Proc. Natl. Acad. Sci. USA 100: 3392-3397.
9. + memory T cells by opposing cytokines. Science 288: 675-678.
10. + T cells. J. Immunol. 170: 5018-5026.
11. Fehniger, T. A., M. A. Cooper, and M. A. Caligiuri. 2002. Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev. 13: 169-183.
12. Waldmann, T. A., S. Dubois, and Y. Tagaya. 2001. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity 14: 105-110.
13. + T cells. Proc. Natl. Acad. Sci. USA 101: 1969-1974.
14. Tagaya, Y., R. N. Bamford, A. P. DeFilippis, and T. A. Waldmann. 1996. IL-15: a pleiotropic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels. Immunity 4: 329-336.
15. Bamford, R. N., A. P. Battiata, J. D. Burton, H. Sharma, and T. A. Waldmann. 1996. Interleukin (IL) 15/IL-T production by the adult T-cell leukemia cell line HuT-102 is associated with a human T-cell lymphotrophic virus type I region IL-15 fusion message that lacks many upstream AUGs that normally attenuates IL-15 mRNA translation. Proc. Natl. Acad. Sci. USA 93: 2897-2902.
16. Bamford, R. N., A. P. DeFilippis, N. Azimi, G. Kurys, and T. A. Waldmann. 1998. The 5′ untranslated region, signal peptide, and the coding sequence of the carboxyl terminus of IL-15 participate in its multifaceted translational control. J. Immunol. 160: 4418-4426.
17. Salter, R. D., D. N. Howell, and P. Cresswell. 1985. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics 21: 235-246.
18. Hughes, M. S., Y. Y. Yu, M. E. Dudley, Z. Zheng, P. F. Robbins, Y. Li, J. Wunderlich, R. G. Hawley, M. Moayeri, S. A. Rosenberg, et al. 2005. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum. Gene Ther. 16: 457-472.
19. Hofacker, I. L. 2003. Vienna RNA secondary structure server. Nucleic Acids Res. 31: 3429-3431.
20. Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, M. E. Dudley, S. L. Schwarz, P. J. Spiess, et al. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4: 321-327.
21. Onodera, M., A. Yachie, D. M. Nelson, H. Welchlin, R. A. Morgan, and R. M. Blaese. 1997. A simple and reliable method for screening retroviral producer clones without selectable markers. Hum. Gene Ther. 8: 1189-1194.
22. Plavec, I., M. Agarwal, K. E. Ho, M. Pineda, J. Auten, J. Baker, H. Matsuzaki, S. Escaich, M. Bonyhadi, and E. Bohnlein. 1997. High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: implication for gene therapy of AIDS. Gene Ther. 4: 128-139.
23. Auten, J., M. Agarwal, J. Chen, R. Sutton, and I. Plavec. 1999. Effect of scaffold attachment region on transgene expression in retrovirus vector-transduced primary T cells and macrophages. Hum. Gene Ther. 10: 1389-1399.
24. Parkman, R., K. Weinberg, G. Crooks, J. Nolta, N. Kapoor, and D. Kohn. 2000. Gene therapy for adenosine deaminase deficiency. Annu. Rev. Med. 51: 33-47.
25. Liu, K., and S. A. Rosenberg. 2003. Interleukin-2-independent proliferation of human melanoma-reactive T lymphocytes transduced with an exogenous IL-2 gene is stimulation dependent. J. Immunother. 26: 190-201.
26. c-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways. Immunol. Rev. 202: 67-83.
27. + T cells exhibit markedly reduced levels of Bcl-2 and Bcl-xL. J. Immunol. 172: 4444-4453.
28. Rocha, E. P. 2004. Codon usage bias from tRNA's point of view: redundancy, specialization, and efficient decoding for translation optimization. Genome Res. 14: 2279-2286.
29. Narum, D. L., S. Kumar, W. O. Rogers, S. R. Fuhrmann, H. Liang, M. Oakley, A. Taye, B. K. Sim, and S. L. Hoffman. 2001. Codon optimization of gene fragments encoding Plasmodium falciparum merzoite proteins enhances DNA vaccine protein expression and immunogenicity in mice. Infect. Immun. 69: 7250-7253.
30. Bradel-Tretheway, B. G., Z. Zhen, and S. Dewhurst. 2003. Effects of codon-optimization on protein expression by the human herpesvirus 6 and 7 U51 open reading frame. J. Virol. Methods 111: 145-156.
31. Cid-Arregui, A., V. Juarez, and H. zur Hausen. 2003. A synthetic E7 gene of human papillomavirus type 16 that yields enhanced expression of the protein in mammalian cells and is useful for DNA immunization studies. J. Virol. 77: 4928-4937.
32. Wang, H., D. J. O'Mahony, D. J. McConnell, and S. Z. Qi. 1993. Optimization of the synthesis of porcine somatotropin in Escherichia coli. Appl. Microbiol. Biotechnol. 39: 324-328.
33. Kirkpatrick, R. B., P. J. McDevitt, R. E. Matico, S. Nwagwu, S. H. Trulli, J. Mao, D. D. Moore, A. F. Yorke, M. M. McLaughlin, K. A. Knecht, et al. 2003. A bicistronic expression system for bacterial production of authentic human interleukin-18. Protein Expr. Purif. 27: 279-292.
34. Wu, X., H. Jornvall, K. D. Berndt, and U. Oppermann. 2004. Codon optimization reveals critical factors for high level expression of two rare codon genes in Escherichia coli: RNA stability and secondary structure but not tRNA abundance. Biochem. Biophys. Res. Commun. 313: 89-96.
35. Tagaya, Y., G. Kurys, T. A. Thies, J. M. Losi, N. Azimi, J. A. Hanover, R. N. Bamford, and T. A. Waldmann. 1997. Generation of secretable and non-secretable interleukin 15 isoforms through alternate usage of signal peptides. Proc. Natl. Acad. Sci. USA 94: 14444-14449.
36. Lu, J., R. L. Giuntoli, Jr., R. Omiya, H. Kobayashi, R. Kennedy, and E. Celis. 2002. Interleukin 15 promotes antigen-independent in vitro expansion and long-term survival of antitumor cytotoxic T lymphocytes. Clin. Cancer Res. 8: 3877-3884.
37. Vella, A. T., S. Dow, T. A. Potter, J. Kappler, and P. Marrack. 1998. Cytokine-induced survival of activated T cells in vitro and in vivo. Proc. Natl. Acad. Sci. USA 95: 3810-3815.
38. S) gene expression. Eur. J. Immunol. 26: 294-299.
39. Plas, D. R., J. C. Rathmell, and C. B. Thompson. 2002. Homeostatic control of lymphocyte survival: potential origins and implications. Nat. Immunol. 3: 515-521.
40. Brentjens, R. J., J. B. Latouche, E. Santos, F. Marti, M. C. Gong, C. Lyddane, P. D. King, S. Larson, M. Weiss, I. Riviere, et al. 2003. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med. 9: 279-286.
41. Roychowdhury, S., K. F. May, Jr., K. S. Tzou, T. Lin, D. Bhatt, A. G. Freud, M. Guimond, A. K. Ferketich, Y. Liu, and M. A. Caligiuri. 2004. Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2. Cancer Res. 64: 8062-8067.
42. Kobayashi, H., S. Dubois, N. Sato, H. Sabzevari, Y. Sakai, T. A. Waldmann, and Y. Tagaya. 2005. Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immune-surveillance. Blood 105: 721-727.
43. Lodolce, J. P., P. R. Burkett, D. L. Boone, M. Chien, and A. Ma. 2001. T cell-independent interleukin 15Rα signals are required for bystander proliferation. J. Exp. Med. 194: 1187-1194.
44. Koka, R., P. Burkett, M. Chien, S. Chai, D. L. Boone, and A. Ma. 2004. Cutting edge: murine dendritic cells require IL-15Rα to prime NK cells. J. Immunol. 173: 3594-3598.
45. + T cell homeostasis. J. Exp. Med. 200: 825-834.
46. + T cells is dispensable for T cell memory. Proc. Natl. Acad. Sci. USA 100: 4724-4729.
47. + T cells. J. Exp. Med. 193: 219-231.
48. McInnes, I. B., B. P. Leung, R. D. Sturrock, M. Field, and F. Y. Liew. 1997. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-α production in rheumatoid arthritis. Nat. Med. 3: 189-195.
49. Waldmann, T. A., and Y. Tagaya. 1999. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu. Rev. Immunol. 17: 19-49.
50. Bonini, C., G. Ferrari, S. Verzeletti, P. Servida, E. Zappone, L. Ruggieri, M. Ponzoni, S. Rossini, F. Mavilio, C. Traversari, et al. 1997. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276: 1719-1724.
51. Tiberghien, P., C. Ferrand, B. Lioure, N. Milpied, R. Angonin, E. Deconinck, J. M. Certoux, E. Robinet, P. Saas, B. Petracca, et al. 2001. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood 91: 63-72.